1-16 of 16
Robert Weinkove
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study

Clinical Trials & Observations
Othman Al-Sawaf, Sandra Robrecht, Can Zhang, Stefano Olivieri, Yi Meng Chang, Anna Maria Fink, Eugen Tausch, Christof Schneider, Matthias Ritgen, Karl-Anton Kreuzer, Liliya Sivchev, Carsten Utoft Niemann, Anthony Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah Kilfoyle, Beenish S. Manzoor, Dureshahwar Jawaid, Nnadozie Emechebe, Jacob Devine, Michelle Boyer, Eva D. Runkel, Barbara Eichhorst, Stephan Stilgenbauer, Yanwen Jiang, Michael Hallek, Kirsten Fischer
Journal: Blood
Blood (2024) 144 (18): 1924–1935.
https://doi.org/10.1182/blood.2024024631
Published: 2024
Includes: Supplemental data
Journal Articles

Sustained Benefit of Zanubrutinib vs Ibrutinib in Patients With R/R CLL/SLL: Final Comparative Analysis of ALPINE

Clinical Trials & Observations
Jennifer R. Brown, Barbara Eichhorst, Nicole Lamanna, Susan M O'Brien, M.D., Constantine S. Tam, Lugui Qiu, Wojciech Jurczak, Keshu Zhou, Martin Šimkovič, Jiří Mayer, Amanda Gillespie-Twardy, Alessandra Ferrajoli, Peter Stephen Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Prof., Anders Osterborg, Habte A. Yimer, Megan (Der Yu) Wang, Tommi Salmi, Liping Wang, Jessica Li, Kenneth Wu, Aileen Cleary Cohen, Mazyar Shadman
Journal: Blood
Blood blood.2024024667.
https://doi.org/10.1182/blood.2024024667
Published: 2024
Includes: Supplemental data
Journal Articles

The Impact of Fitness and Dose Intensity on Safety and Efficacy Outcomes after Venetoclax-Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia

Othman Al-Sawaf, Moritz Fürstenau, Adam Giza, Sandra Robrecht, Julia Von Tresckow, Anna Maria Fink, Florian Simon, Eugen Tausch, Christof Schneider, Liliya Sivcheva, Anthony Schwarer, Javier Loscertales, Robert Weinkove, Dirk Strumberg, Allanah R. Kilfoyle, Gunnar Juliusson, Caspar Da Cunha-Bang, Thomas Illmer, Michael Gregor, Patrick Thornton, Ann Janssens, Tamar Tadmor, Vesa Lindström, Philipp Bernhard Staber, Mark-David Levin, Clemens-Martin Wendtner, Karl-Anton Kreuzer, Matthias Ritgen, Stephan Stilgenbauer, Arnon P. Kater, Carsten Utoft Niemann, Kirsten Fischer, Barbara F. Eichhorst, Michael Hallek
Journal: Blood
Blood (2023) 142 (Supplement 1): 4639.
https://doi.org/10.1182/blood-2023-188827
Published: 2023
Journal Articles

Combination Treatment with Sonrotoclax (BGB-11417), a Second-Generation BCL2 Inhibitor, and Zanubrutinib, a Bruton Tyrosine Kinase (BTK) Inhibitor, Is Well Tolerated and Achieves Deep Responses in Patients with Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (TN-CLL/SLL): Data from an Ongoing Phase 1/2 Study

Constantine S. Tam, Mary Ann Anderson, Masa Lasica, Emma Verner, Stephen S. Opat, Shuo Ma, Robert Weinkove, Raul Cordoba, Jacob Soumerai, Paolo Ghia, Sophie Leitch, James Hilger, Yiqian Fang, David Simpson, Haiyi Guo, Chan Yoon Cheah
Journal: Blood
Blood (2023) 142 (Supplement 1): 327.
https://doi.org/10.1182/blood-2023-179541
Published: 2023
Journal Articles

Optimizing Immunoglobulin Replacement Therapy for Patients with B-Cell Malignancies and Hypogammaglobulinemia: The Investigator-Initiated, International, Randomized Phase II/III Rational Platform Trial, and the Rationalise (STOP IgRT) Domain

Erica M. Wood, Khai Li Chai, John Reynolds, Jennifer Griffiths, Brendan Beaton, Jeannie Callum, Kyle R Crassini, Philip J Crispin, Laura Fanning, Michael Gilbertson, Andrew P Grigg, Eliza A Hawkes, C. Orla Morrissey, Stephen P Mulligan, Stephen S. Opat, David L Paterson, Dennis Petrie, Jason A Roberts, Elizabeth G Ryan, Andrew Spencer, Simon J Stanworth, Le Thi Phuong Thao, Judith Trotman, Neil A Waters, Robert Weinkove, Zoe K McQuilten
Journal: Blood
Blood (2023) 142 (Supplement 1): 1295.
https://doi.org/10.1182/blood-2023-181541
Published: 2023
Journal Articles

Extended Follow-up of ALPINE Randomized Phase 3 Study Confirms Sustained Superior Progression-Free Survival of Zanubrutinib Versus Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL)

Jennifer R. Brown, Barbara F. Eichhorst, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Luqui Qiu, Maciej Kaźmierczak, Wojciech Jurczak, Keshu Zhou, Martin Simkovic, Jiri Mayer, Amanda L. Gillespie-Twardy, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Osterborg, Habte A. Yimer, Megan (Der Yu) Wang, Tommi Salmi, Liping Wang, Jessica Li, Kenneth Wu, Aileen Cleary Cohen, Mazyar Shadman
Journal: Blood
Blood (2023) 142 (Supplement 1): 202.
https://doi.org/10.1182/blood-2023-174289
Published: 2023
Journal Articles

A Phase 1 Dose Escalation Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Intracellular Domains for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE)

Robert Weinkove, Philip George, Robert Fyfe, Nathaniel Dasyam, Yasmin Nouri, Tess Ostapowicz, Stefan Mullins, Brigitta Mester, Giulia Giunti, Catherine M. Bollard, Travis Perera, Hayden Jina, Alwyn D'Souza, Le Qin, David S. Ritchie, Chris M.A. Frampton, Rachel Perret, Peng Li, Ian Hermans
Journal: Blood
Blood (2023) 142 (Supplement 1): 890.
https://doi.org/10.1182/blood-2023-178872
Published: 2023
Journal Articles

Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Jennifer R. Brown, Barbara Eichhorst, Peter Hillmen, Nicole Lamanna, Susan M. O'Brien, Constantine S. Tam, Lugui Qiu, Maciej Kaźmierczak, Wojciech Jurczak, Keshu Zhou, Martin Šimkovič, Jiri Mayer, Amanda L. Gillespie-Twardy, Alessandra Ferrajoli, Peter S. Ganly, Robert Weinkove, Sebastian Grosicki, Andrzej Mital, Tadeusz Robak, Anders Österborg, Habte A. Yimer, Tommi Salmi, Megan (Der Yu) Wang, Lina Fu, Jessica Li, Kenneth Wu, Aileen Cohen, Mazyar Shadman
Journal: Blood
Blood (2022) 140 (Supplement 2): LBA-6.
https://doi.org/10.1182/blood-2022-171538
Published: 2022
Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2B Results in High Rates of MR4.5 at 24 Months - Primary Analysis of the ALLG CML 11 Pinnacle Study

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Naranie Shanmuganathan, MBBS FRACP FRCPA, Andrew Grigg, Ilona Cunningham, MBBS FRACP FRCPA, Jake Shortt, FRACP,FRCPA,PhD, Philip Rowling, MBBS FRACP FRCPA, John Reynolds, PhD, Rosemary Anne Harrup, MBBS, FRACP, FRCPA, David M Ross, MD PhD, David Kipp, MBBS,FRCPA,FRACP, Anthony K Mills, FRACP, FRCPA, MBBS, Christopher K Arthur, MBBS FRACP FRCPA, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Kathryn Jackson, MBBS FRACP FRCPA, Nicholas Viiala, MBBS FRACP FRCPA, Robert Weinkove, MD, Agnes S. M. Yong, MD PhD, Deborah L. White, PhD FFSc (RCPA), Susan Branford, PhD, Timothy P. Hughes, MDMBBS,FRACP,FRCPA, On Behalf of the ALLG
Journal: Blood
Blood (2019) 134 (Supplement_1): 2926.
https://doi.org/10.1182/blood-2019-125740
Published: 2019
Journal Articles

Combination of Nilotinib and Pegylated Interferon Alfa-2b Results in High Molecular Response Rates in Chronic Phase CML: Interim Results of the ALLG CML 11 Pinnacle Study

David T Yeung, PhDBSc,FRACP,FRCPA,MBBS, Andrew P. Grigg, MBBS, FRACP, FRCPA, MD, Naranie Shanmuganathan, MBBS, Ilona Cunningham, MBBS FRACP FRCPA, Jake Shortt, FRACP,FRCPA,PhD, Philip Rowling, MBBS FRACP FRCPA, John Reynolds, PhD, Rachel Cushion, Rosemary Anne Harrup, MD, David M Ross, David Kipp, MBBS,FRCPA,FRACP, Anthony K Mills, FRACP, FRCPA, MBBS, Christopher K Arthur, Anthony P Schwarer, MD MBBS(Hons), FRACP, FRCPA, Kathryn Jackson, MBBS FRACP, FRCPA, Nicholas Viiala, MBBS, FRACP, FRCPA, Robert Weinkove, MA, MBBS, PhD, FRCPath, FRACP, Agnes S. M. Yong, MD, PhD, Deborah L White, PhD, Susan Branford, PhD, Timothy P. Hughes, MD, MBBS, FRACP, FRCPA, On Behalf of the ALLG
Journal: Blood
Blood (2018) 132 (Supplement 1): 459.
https://doi.org/10.1182/blood-2018-99-110569
Published: 2018
Journal Articles

Nilotinib in Combination with Pegylated Interferon Alfa-2b for CP-CML Leads to High Molecular Response Rates: Interim Results of the Pinnacle Study

David Yeung, PhDBSc,FRACP,FRCPA,MBBS, Andrew Grigg, MBBS FRACP FRCPA, Naranie Shanmuganathan, MBBS, Ilona Cunningham, MBBS FRACP FRCPA, Jake Shortt, MBBS PhDFRACP FRCPA, Philip Rowling, MBBS FRACP FRCPA, John Reynolds, PhD, Rachel Cushion, Rosemary Harrap, MBBS FRACP FRCPA, David M Ross, MBBS, PhD FRACP, FRCPA, David Kipp, MBBS,FRCPA,FRACP, Anthony K Mills, FRACP, FRCPA, MBBS, Christopher K Arthur, MDFRACP,FRCPA,MBBS, Anthony P Schwarer, MD MBBS (Hons), FRACP, FRCPA, Kathryn Jackson, MBBS FRACP FRCPA, Nicholas Viiala, MBBS FRACP FRCPA, Robert Weinkove, MA, MBBS, PhD FRCPath, FRACP, Agnes S. M. Yong, MDPhD, Deborah L White, PhD FFSc (RCPA), Susan Branford, PhD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA
Journal: Blood
Blood (2017) 130 (Supplement 1): 2898.
https://doi.org/10.1182/blood.V130.Suppl_1.2898.2898
Published: 2017
Journal Articles

Venetoclax and obinutuzumab in chronic lymphocytic leukemia

Clinical Trials & Observations
Kirsten Fischer, Othman Al-Sawaf, Anna-Maria Fink, Mark Dixon, Jasmin Bahlo, Simon Warburton, Thomas J. Kipps, Robert Weinkove, Sue Robinson, Till Seiler, Stephen Opat, Carolyn Owen, Javier López, Kathryn Humphrey, Rod Humerickhouse, Eugen Tausch, Lukas Frenzel, Barbara Eichhorst, Clemens-M. Wendtner, Stephan Stilgenbauer, Anton W. Langerak, Jacque J. M. van Dongen, Sebastian Böttcher, Matthias Ritgen, Valentin Goede, Mehrdad Mobasher, Michael Hallek
Journal: Blood
Blood (2017) 129 (19): 2702–2705.
https://doi.org/10.1182/blood-2017-01-761973
Published: 2017
Includes: Supplemental data
Journal Articles

Safety and Efficacy of Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) and Coexisting Medical Conditions: Final Results of the Run-in Phase of the Randomized CLL14 Trial (BO25323)

Kirsten Fischer, MD, Othman Al-Sawaf, MD, Anna-Maria Fink, MD, Mark Dixon, BSc MSC, Jasmin Bahlo, Simon Warburton, MSc, Thomas J. Kipps, MD, PhD, Robert Weinkove, MD PhD, Sue Robinson, MD, Martin H. Dreyling, MD PhD, Stephen Opat, MD, Carolyn J. Owen, MD MDes(UK), FRCPC, Javier López, MD PhD, Kathryn Humphrey, PhD, Rod A. Humerickhouse, MD, Eugen Tausch, Barbara Eichhorst, MD, Clemens-M. Wendtner, MD, Anton W. Langerak, Jacques J.M. van Dongen, MD PhD, Matthias Ritgen, Sebastian Boettcher, MD, Stephan Stilgenbauer, Valentin Goede, MD, Mehrdad Mobasher, MD, Michael Hallek
Journal: Blood
Blood (2016) 128 (22): 2054.
https://doi.org/10.1182/blood.V128.22.2054.2054
Published: 2016
Journal Articles

Results of the Safety Run-in Phase of CLL14 (BO25323): A Prospective, Open-Label, Multicenter Randomized Phase III Trial to Compare the Efficacy and Safety of Obinutuzumab and Venetoclax (GDC-0199/ABT-199) with Obinutuzumab and Chlorambucil in Patients with Previously Untreated CLL and Coexisting Medical Conditions

Kirsten Fischer, MD, Anna-Maria Fink, MD, Helen Bishop, Mark Dixon, Jasmin Bahlo, Michael Y. Choi, MD, Robert Weinkove, MD PhD, K. Sue Robinson, MD, Martin Dreyling, MD PhD, Till Seiler, MD, Stephen Opat, MD, Carolyn Owen, MD, Javier Lopez, Sr., MD PhD, Nadine Kutsch, MD, Eugen Tausch, MD, Matthias Ritgen, MD, Rod A. Humerickhouse, MD PhD, Kathryn Humphrey, Michael K. Wenger, MD, Valentin Goede, MD, Barbara Eichhorst, MD, Clemens-Martin Wendtner, MD, Stephan Stilgenbauer, MD, Thomas J. Kipps, MD PhD, Michael Hallek, MD
Journal: Blood
Blood (2015) 126 (23): 496.
https://doi.org/10.1182/blood.V126.23.496.496
Published: 2015
Journal Articles

An autologous leukemia cell vaccine prevents murine acute leukemia relapse after cytarabine treatment

John D. Gibbins, Lindsay R. Ancelet, Robert Weinkove, Benjamin J. Compton, Gavin F. Painter, Troels R. Petersen, Ian F. Hermans
Journal: Blood
Blood (2014) 124 (19): 2953–2963.
https://doi.org/10.1182/blood-2014-04-568956
Published: 2014
Includes: Supplemental data
Journal Articles

A  High- Risk Genetic Signature Is Predictive For Poor Outcome In Auto-Transplant Eigible Multiple Myeloma Patients Even With Use Of Novel Agents. A Single Institution Study

Kenneth R. Romeril, FRACP, FRCPA, Huib Buyck, Richard Parfitt, Catherine Wood, Alwyn d'Souza, Robert Weinkove, MA, FRCPath
Journal: Blood
Blood (2013) 122 (21): 5371.
https://doi.org/10.1182/blood.V122.21.5371.5371
Published: 2013